Roche and Nurix Therapeutics to partner in $2.3bn deal

08 Jun 2026
·
Deals
pmlive.com
License out/inPhase 3
Roche and Nurix Therapeutics have announced the two companies will partner in an exclusive licensing and collaboration agreement worth up to $2.3bn.
RocheollabNurix Therapeuticsevelop and co-commercialise bexobrutideg (NX-5948), Nurix’s investigational Bruton’s Tyrosine Kinase (BTK) degrader. The collaboration encompasses a clinical development plan spanning B-cell malignancies, immunology and neurology.
Patients with B-cell–driven malignancies continue to facbexobrutideg (NX-5948)edNurixite advances with BBruton’s Tyrosine Kinase (BTK)ies. In haematology, many patients with CLL ultimately experience disease progB-cell malignanciesired resistance mutations, incomplete pathway suppression, or intolerance that limits long-term use, and treatment options remain limited once patients relapse.
Levi Garraway,B-cell–driven malignancieser and Head of Global Product Development, commented: “We belieBTK inhibitorsBTKbexobrutideg could represent a major leap forward in the fight againCLLcomplex blood cancers and other diseases.”
The addition ofRochebrutideg complements Roche’s existing strengths in haematology and provides a cross-thbexobrutidegportunity to extend the pipeline’s reach in immunology and neurologblood cancersinical trials for bexobrutideg are expected to start in Q2 2026.
Arthur Sands, prbexobrutidegCEO of Nurix Rochepeutics, said: “As a single agent, bexobrutideg has shown highly promising results in B cell malignancy clinical trials to date and we can now rapidly expand our phase 3 bexobrutideg
The parties currently expect the trNurix Therapeutics in the third quarter of 202bexobrutidegB cell malignancy
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!